Filing Details
- Accession Number:
- 0001567619-21-005540
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-03 16:48:47
- Reporting Period:
- 2021-03-01
- Accepted Time:
- 2021-03-03 16:48:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787306 | Arcutis Biotherapeutics Inc. | ARQT | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559583 | W John Smither | C/O Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village CA 91361 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-03-01 | 773 | $34.20 | 24,425 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 87,965 | Indirect | By Trust |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021.
- Includes 6,750 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
- The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.